DI BELLA METHOD
>
DOCUMENTATION INDEX > MDB - Documents
Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
(30/05/2003)
Detail
Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma.
(30/05/2003)
Detail
Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
(30/05/2003)
Detail
Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
(30/05/2003)
Detail
Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
(30/05/2003)
Detail
The glucagonoma syndrome: a review of its features and discussion of new perspectives.
(30/05/2003)
Detail
Somatostatin up-regulates topoisomerase II alpha expression and affects LNCaP cell cycle.
(30/05/2003)
Detail
Somatostatin in neuroblastoma and ganglioneuroma.
(30/05/2003)
Detail
(131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
(30/05/2003)
Detail
Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen]
(30/05/2003)
Detail
Primary cerebral lymphoma visualised by means of In-111-pentetreotide scintigraphy.
(30/05/2003)
Detail
Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology.
(30/05/2003)
Detail
Localization of small-cell lung cancer xenografts with iodine-125-, indium-111-, and rhenium-188-somatostatin analogs.
(30/05/2003)
Detail
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
(30/05/2003)
Detail
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
(30/05/2003)
Detail